PRF Technologies Ltd. (PRFX)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.8843−3.88%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $3.1M
- 52-week range
- $0.852 – $7.95
- 52-week change
- −86.47%
- EPS (trailing)
- −$4.09
Fiscal year to Dec 2025
- Revenue
- $17K
- Net income
- −$5.0M
- Operating margin
- −30129.4%
- Diluted EPS
- −$7.47
- Free cash flow
- −$4.0M
From the company’s annual report on SEC EDGAR.
About PRF Technologies Ltd.
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
Headquarters: Tel Aviv, Israel · 6 employees · painreform.com